Logo Image
|Videos|December 13, 2021

Dr. Morris on Lutetium 177 PSMA: “We have a lot of work to do”

We have a lot of work to do to define how to optimize the integration of this therapy into what we call ‘advanced prostate cancer’,” says Michael J. Morris, MD.

In this video, Michael J. Morris, MD, discusses what the impact of the VISION trial will be on clinical practices, which are ideas that were focused on at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more